Objective: Although adiposity has been considered to be protective against hot flashes, newer data suggest positive relationships between hot flashes and adiposity. No studies have been specifically designed to test whether weight loss reduces hot flashes. This pilot study aimed to evaluate the feasibility, acceptability, and initial efficacy of behavioral weight loss in reducing hot flashes.
H ot flashes are a prevalent menopausal symptom, with more than 70% of women reporting hot flashes during the menopausal transition. 1 In many cases, these symptoms are frequent or severe. 1<3 Newer data also indicate that hot flashes are persistent, lasting an average of 9 years or more. 4 Women with hot flashes are at greater risk for poor quality of life, 5 sleep problems, 6 and depressed mood 7 than women without hot flashes. Thus, women frequently seek treatment for their hot flashes, which are a leading driver of gynecologic ambulatory care visits 8 and out-of-pocket gynecologic expenditures. 9 In light of potential risks associated with hormone therapy, 10 which is the most effective treatment of hot flashes, there is great interest in nonhormone methods, including behavioral approaches, for managing hot flashes.
11
One potential behavioral approach to managing hot flashes is weight loss. 12 However, the role that body weight plays in the occurrence of hot flashes during the menopausal transition has been the subject of debate. Given that adipose tissue is a site for the peripheral conversion of androgens into estrogens, body fat was initially theorized to be protective against hot flashes. 13 However, more recent epidemiologic investigations have challenged this idea, as cross-sectional data indicated that women with higher body mass index (BMI) and higher body fat reported more hot flashes than their leaner counterparts. 1 Moreover, longitudinal data indicated that increasing body fat during the menopausal transition was associated with higher subsequent hot flash reporting.
14 These data were consistent with the thermoregulatory role of body fat, with adipose tissue insulating against the putative heat-dissipating action of hot flashes. 15, 16 In addition, data suggested that the relationship between adiposity and hot flashes may vary according to menopause stage. Higher adiposity may act as a risk factor earlier in the menopausal transition and may be protective later in the menopausal transition when ovarian estrogen production has ceased. 17<19 Thus, the positive association between adiposity and hot flashes may be limited to the early menopausal transition. Existing research on adiposity and hot flashes has been largely observational, limiting conclusions about the causal role of body fat in hot flash occurrence. Post hoc analyses of two existing trials have provided a preliminary suggestion that weight loss may reduce the occurrence of hot flashes or the bother associated with hot flashes, 20, 21 although findings were mixed and did not provide clear answers to the question of whether weight loss reduces hot flashes. 22 Notably, these existing data were derived from secondary analyses of trials not designed to address whether weight loss reduced hot flashes and thus had important limitations, including a low representation of women with hot flashes, inclusion of women using medications to reduce hot flashes (eg, hormone therapy), and assessment of hot flashes via brief retrospective questionnaire instruments. To date, there have been no experimental manipulations specifically designed to test whether weight loss reduces hot flashes. Furthermore, it is unclear whether behavioral weight loss for hot flash reduction would be acceptable to women with hot flashes and whether reduction of hot flashes would motivate women to engage in this healthpromoting behavior.
The primary aim of this pilot study was to evaluate the feasibility and acceptability of a behavioral weight loss intervention for reducing hot flashes. Second, we examined the preliminary effect of this weight loss intervention on hot flashes, particularly whether women in the weight loss group showed greater reductions in hot flashes than women in the control group. Furthermore, in an exploratory fashion, we investigated whether degree of weight change was related to degree of hot flash change. Finally, we examined whether any weight lossYassociated reduction in hot flashes varied by proximity to the final menstrual period (FMP), which is a proxy for ovarian aging.
METHODS

Study participants
Forty overweight or obese (BMI, 25-40 kg/m 2 ) women experiencing 4 or more hot flashes/day who wanted to lose weight were recruited from the surrounding community via hospital registries, fliers at local businesses and hospitals, and online message boards. Women were either late perimenopausal (amenorrhea for 3-12 mo) or postmenopausal (amenorrhea for Q12 mo). Sample exclusion criteria included hysterectomy/ oophorectomy or use of medications known to impact hot flashes, weight, or both (hormone therapy, oral contraceptives, gabapentin, selective serotonin reuptake inhibitors/serotoninnorepinephrine reuptake inhibitors, selective estrogen receptor modulators, clonidine, antipsychotics, steroids, weight loss medications, and chemotherapy). Women also were excluded if they were currently participating in a structured weight loss program, had ever undergone weight loss surgical operation, or were currently engaging in more than 150 minutes/week of physical activity with a BMI lower than 27.5 kg/m 2 . All women obtained a written medical clearance from their personal physician to participate in a lifestyle weight loss program and provided a written informed consent form. Study procedures were approved by the University of Pittsburgh Institutional Review Board.
Protocol
Women completed a telephone assessment and a subsequent in-person assessment to determine study eligibility. Eligible women underwent baseline hot flash monitoring, measurement of height and weight, and dual-energy x-ray absorptiometry (DXA) assessment of body composition, and answered questionnaires. Women were next randomly assigned to a weight loss arm or a control arm in approximate blocks of 10. Participants in the experimental condition were invited to attend 20 group sessions delivered weekly for 6 months. The hot flash, height, weight, DXA, and questionnaire assessments were repeated after this 6-month period. The control condition was a wait-list control. Women in the control condition underwent assessments at baseline and 6 months and were invited to attend separate weight loss group sessions after completing all assessments.
Measures
Screening measures included measurement of height and weight, medical history, medication use, and reproductive history, including assessment of menstrual cycles. The approximate date of the last menstrual period was reported.
Anthropometric
Height and weight were measured using a fixed stadiometer (Seca, Hanover, MD) and a calibrated balance beam scale (Healthometer, Alsip, IL), respectively. BMI was calculated (kg/m 2 ).
Dual-energy x-ray absorptiometry
Body composition was assessed using DXA, a validated measure of body composition. 15 Measurements were performed at the University of Pittsburgh Endocrinology and Metabolism Research Center using a Luna r-iDEXA machine with enCORE v.12.30 software (GE Healthcare, Fairfield, CT). Total percentage of body fat was derived from this measurement.
Hot flashes
Hot flashes were measured in three ways: (1) physiologic assessment, (2) electronic diary, and (3) questionnaire.
Physiologic hot flashes. Women were equipped with a physiologic hot flash monitor, the Biolog (3991/2-SCL; UFI, Morro Bay, CA), which they wore in a pouch around the waist for 24 hours. Skin conductance was sampled at 1 Hz from the sternum via a 0.5-V constant voltage circuit passed between two Ag/AgCl electrodes (UFI) filled with 0.05 M KCl Velvachol/glycol paste. 23 Physiologic hot flashes were classified via standard methods, with skin conductance increases of 2 or more Hmho/30 seconds 24 flagged automatically by UFI software (DPSv3.6) and edited for artifact. 25 As some women showed submaximal events (failing to reach the 2-Hmho criterion), 26, 27 all potential hot flashes were visually inspected by hot flash coders; events showing the characteristic hot flash pattern but less than 2 Kmho/30 seconds were coded as a hot flash. This coding has been shown in our laboratories to be reliable (J = 0.86).
26,27 A 20-minute lockout period was implemented after the start of a hot flash, during which no further events were coded.
Diary-reported hot flashes. Using a handheld electronic diary (Palm Z22; Palm Inc, Sunnyvale, CA), women reported their hot flashes at the time of hot flash occurrence for 3 days. The first of which coincided with physiologic monitoring. Each hot flash was also rated on severity and bother (1, mild; 2, moderate; 3, severe; 4, very severe). This 3-day monitoring period was chosen based on prior work indicating that 3 days of diary monitoring yields estimates comparable to a week. 28 Questionnaire-assessed hot flashes. For comparability with other investigations, 1, 16, 17 women were asked to report via questionnaire the frequency of their hot flashes during the past 2 weeks (number of days experiencing hot flashes: 1-5 d, 6-8 d, 9-13 d, or every day; number of hot flashes per day). The number of hot flashes per day was multiplied by the number of days experiencing hot flashes to yield the number of hot flashes for 2 weeks.
Other questionnaires
Women completed a battery of questionnaires, including demographics (eg, age, race/ethnicity, educational attainment), health behaviors (eg, smoking, physical activity as assessed with the International Physical Activity Questionnaire), 29 and psychosocial factors (eg, depressive symptoms as assessed with the Center for Epidemiologic Studies Depression Scale). 30 
Intervention acceptability
After each intervention session, women were asked to rate the session with respect to usefulness (0, not at all; 4, very). At the end of the intervention, women were asked how satisfied they were with the program (0, very dissatisfied; 4, very satisfied) and their reasons for joining the study (appearance, hot flash reduction, other health reasons [eg, hypertension, diabetes, orthopedic], other quality-of-life reasons [eg, mood, sleep, energy], advice from healthcare provider, other). They were also asked whether the potential to reduce hot flashes with weight loss influenced their motivation to lose weight (0, decreased a lot; 4, increased a lot) and whether their motivation to lose weight during midlife/ menopause was different from their motivation at other times of life.
Weight loss intervention
The intervention was a standard behavioral weight loss intervention that included dietary and physical activity selfmonitoring, prescription of moderate calorie reduction, and encouragement of moderate physical activity. Sessions were delivered in twenty 1-hour group sessions (10-14 women per group) for 6 months. Each session included a weigh-in, review of self-monitoring forms with written feedback, and didactics. The intervention is similar to those in the Look AHEAD study 31 and the Diabetes Prevention Program 32 and follows National Heart, Lung, and Blood Institute clinical guidelines for obesity treatment. 33 Women were provided with calorie goals based on initial body weight (1,200-1,800 kcal/d), given physical activity goals (eg, brisk walking for 100-300 min/wk), and instructed on key behavioral strategies such as stimulus control and selfmonitoring of weight and calories. The intervention was additionally tailored to midlife women, addressing issues such as dietary and activity choices in the context of sleep loss; behavior change in the context of family, work, and caretaking demands; and physical activity choices with aging.
Data analysis
All indices were examined for normality, outliers, and smaller cell sizes. Ambulatory physiologic and diary hot flash indices were standardized to a 24-hour period to account for variations in monitoring duration. To do so, the number of hot flashes (physiologic or diary-reported) was divided by the monitoring duration and multiplied by 24. Diary-reported severity and bother ratings for each hot flash were averaged over the number of hot flashes reported.
Characteristics of women randomized to the experimental condition versus the control condition, as well as those of completers versus dropouts, were compared via t tests and W 2 tests. Completers were defined as women who completed the 6-month (postintervention) follow-up assessment. Preintervention to postintervention changes in hot flashes, weight, and body fat were calculated as change scores. Differences in hot flashes and weight change between intervention and control were compared via Wilcoxon rank sum tests. Analyses were conducted for both completers and as intent-to-treat (baseline hot flash values carried forward for the missing 6-month follow-up hot flash values). Analyses were conducted with SAS software. All tests were two-sided at an > of 0.05.
RESULTS
Forty women (25% African American and 75% white) were enrolled. At baseline, women had median (interquartile range [IQR]) physiologic hot flashes of 8.86 (4.99 to 13.47) and median (IQR) self-reported hot flashes per 24 hours of 6.41 (4.93 to 9.80). Their mean (SD) baseline BMI was 32.13 (3.79) kg/m 2 , and their mean (SD) percent total body fat was 44.84 (4.50). Women randomized to weight loss versus control were similar on all study characteristics (Table 1) .
Retention was high and did not differ between groups, with 83% of women completing the study (intervention, 81.0%; control, 84.2%; P = 1.00; see Fig. for study flow chart) . Women who completed the study did not differ from women who did not complete the study on any characteristic, except for a marginally lower percent body fat before treatment (completers, 44.5%; noncompleters, 47.5%; P = 0.07). Women in the intervention condition attended a median of 16 (80%) weight loss sessions. On average, women rated the sessions high on usefulness (mean [SD], 3.76 [0.25]; 0, not at all useful; 4, very useful). Women in the intervention group also reported being satisfied (6.3%) or very satisfied (93.8%) with the intervention. Session ratings of usefulness and amount of weight loss were significantly correlated (Q = 0.52, P = 0.03).
Women were asked why they participated in this weight loss study. The leading reasons that women cited for wanting to lose weight were appearance (81.5%), hot flash reduction (74.1%), and improved quality of life (70.4%). Most of the women (81.5%) indicated that the potential to reduce hot flashes increased their motivation to lose weight (Bby a lot[ for 51.9% of women). Approximately half (51.9%) of the women indicated that their motivation to lose weight was higher during the menopausal transition than at other times of life.
Women in the intervention group lost an average of 8.8 kg (10.7%) and 4.7% body fat from baseline to the 6-month postintervention assessment (Table 2) , with similar yet slightly attenuated changes in intent-to-treat analyses (7.5 kg; change, 3.8% body fat; Table 3 ). There was little weight or body composition change in the control group. Women in the intervention group also showed a tendency toward greater reduction in hot flashes compared with women in the control group. This difference was significant in the case of questionnaire-reported hot flashes, but not diary-reported or monitored hot flash frequency. The amount of weight reduction correlated with reductions in questionnaire-reported hot flash frequency and diary-reported hot flash severity (Table 4) .
We explored whether changes in hot flashes in response to the intervention varied by time since the FMP, which is an indicator of ovarian aging. Although not statistically significant (interactions by time since FMP, P's = 0. 18 . Correlations between changes in weight and diary-reported hot flashes were also more pronounced among women earlier in the menopausal transition (e5 y since FMP: r = 0.41, P = 0.06; 95 y since FMP: r = j0.02, P = 0.95).
DISCUSSION
This pilot clinical trial indicates that a behavioral weight loss intervention for midlife women with hot flashes is feasible and acceptable. It also successfully produced weight loss at a magnitude similar to other behavioral weight loss trials. 33 Furthermore, the degree of weight loss correlated with the degree of As assessed with the International Physical Activity Questionnaire. As assessed with the Center for Epidemiologic Studies Depression Scale. reduction in hot flashes. This pilot study was designed to assess the feasibility and acceptability of this intervention in this population and was not powered to detect intervention-associated changes in hot flashes. However, preliminary findings show greater reductions in questionnaire-reported hot flashes in the weight loss group relative to the control group among women completing the trial, suggesting the potential value of a larger trial in assessing weight loss for hot flash reduction. Diary HF bother and HF severity scores ranged from 1 to 4 and were averaged across the monitoring period. Questionnaire HF frequency refers to recalled frequency of HF for the past 2 weeks (number of HF per day Â number of days experiencing HF). Differences were tested via Wilcoxon test. HF, hot flashes.
Our findings support the acceptability and feasibility of this intervention, as session attendance, retention rates during the study period, and satisfaction were high. Women in the intervention groups attended, on average, 80% of the sessions. Participants rated the intervention highly on utility and satisfaction and reported that hot flash reduction was a major motivator for losing weight. These findings are relevant, as more silent conditions may not provide sufficient motivation for women to lose weight. Thus, the possibility of reductions in the often bothersome symptom of hot flashes may be an important motivator for women to engage in weight lossYrelated behaviors.
Women who completed the intervention lost more than 10% of their body weight and 5% of their body fat, which were associated with improvement in self-reported hot flashes. This amount of weight loss is clinically significant (eg, associated with improvements in lipids, insulin sensitivity, and blood pressure). 33 Although this study was not powered to detect interventionassociated changes in hot flashes, there was some indication of greater reductions in hot flashes in response to the intervention rather than the control. In fact, questionnaire-reported hot flashes showed a pronounced reduction in response to the intervention (decreased by 63 hot flashes/2 wk or 4.5 hot flashes/d). Furthermore, reductions in reported hot flashes were correlated with reductions in weight, supporting a potential causal role of weight change in hot flash reduction.
These data add to the very limited existing literature on weight loss and hot flashes. To date, only two post hoc analyses of existing trials have examined weight loss interventions in relation to hot flashes. One study analyzed data from a behavioral weight loss trial among overweight and obese women with urinary incontinence, finding improvements in ratings of hot flash bother among women randomized to intervention. 20 A second analysis from the Women's Health Initiative Dietary Modification Study, which assessed the occurrence and severity of hot flashes, produced conflicting resultsVa decrease in recalled hot flashes in women who, paradoxically, both gained and lost weight. 21 Although these analyses provide important initial examinations of this topic, they were not designed to address this question. They had limitations such as brief hot flash measures and inclusion of primarily postmenopausal women, only a subset of whom were experiencing hot flashes and some of whom were using medications to treat hot flashes. Menopause stage was not considered. Together with the existing pilot trial, these studies underscore the importance of future well-powered trials specifically designed to address whether weight loss reduces hot flashes. Such trials could lend insights into the direction of relationships between adiposity and hot flashes and could point to a behavioral method for managing hot flashes that also has other salubrious effects.
In this study, hot flashes were measured via several different modalities, including physiologic monitoring, diary, and questionnaire. Although women in the weight loss group showed reductions across modalities, our findings were significant only for questionnaire-reported hot flashes. This pattern was evident for the changes in hot flashes in response to the intervention, as well as associations between hot flashes and weight loss. Why findings were noted principally for questionnaire-rated hot flashes is not immediately clear. Questionnaire-reported hot flashes differed from the other measures of hot flashes in that they were recalled during a 2-week period and thus encompassed a longer period than the 24-hour or 3-day physiologic or diary measures, respectively. Because these hot flashes are recalled, these estimates incorporate the influence of memory, which could potentially be influenced by intervention group participation. Prior work has indicated that hot flash measures differ in important ways. 34, 35 Results of prior post hoc analyses of clinical weight loss trials were based solely on questionnaire-reported hot flashes. 20, 21 These findings further underscore that all hot flash measures are not interchangeable and indicate the importance of conducting a well-powered trial using state-of-the art measures of hot flashes to assess changes in hot flashes in response to weight loss.
Prior work has indicated that the direction of relationships between adiposity and hot flashes may change during the course of the menopausal transition, with positive associations between adiposity and hot flashes early in the menopausal transition and inverse associations later in the menopausal transition. 17<19 The reasons for this reversal are not entirely clear. However, there is evidence to indicate that the role of adiposity in estrogen production may vary by age or menopause stage, 36, 37 which would in turn influence hot flash occurrence. Early in the menopausal transition, higher adiposity may impair ovarian estradiol production; whereas later in the menopausal transition when ovarian function has ceased, body fat may be a key source of estrogen (estrone). We found suggestive evidence for stronger reductions in reported hot flashes and more pronounced associations between changes in adiposity and changes in reported hot flashes among women who were closer to their FMP. However, these findings were highly exploratory and must be viewed with caution. The sample size was small, and this study was not designed to address any differential effect of weight loss on hot flashes by ovarian aging (eg, early perimenopausal women were not included). These findings indicate the potential importance of assessing any differential effect of weight loss by ovarian aging in future work.
This study had several limitations. As it was a pilot study designed to assess feasibility and acceptability, the sample size was modest. The control condition was a wait-list control rather than an active control. Although no significant differences were noted between women who completed the intervention and those who dropped out, the small sample size precludes firm conclusions that these women did not differ. Nonetheless, this study is the first study specifically designed to test a behavioral weight CONCLUSIONS This study indicates that a behavioral weight loss intervention can be acceptable and feasible among overweight and obese midlife women with hot flashes. It also suggests the potential promise of a weight loss intervention for hot flash reduction that should be evaluated more fully in future work. Based on this demonstration of acceptability and feasibility, the next step is a well-powered trial designed to test the impact of behavioral weight loss on hot flashes. The possibility of symptomatic relief for this bothersome midlife symptom may motivate women to engage in this important health-promoting behaviorVa behavior that may not only improve quality of life but also reduce later disease as women enter their postmenopausal years.
